Comparative Pharmacology
Head-to-head clinical analysis: EMBEDA versus VICOPRIN.
Head-to-head clinical analysis: EMBEDA versus VICOPRIN.
EMBEDA vs VICOPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EMBEDA is a combination of morphine sulfate, a full opioid agonist, and naltrexone hydrochloride, an opioid antagonist. Morphine binds to mu-opioid receptors in the CNS, altering pain perception and response. Naltrexone is sequestered in the core and is released if the pellets are crushed or chewed, potentially precipitating withdrawal or blockade of morphine effects.
VICOPRIN (hydrocodone/acetaminophen) combines a mu-opioid receptor agonist (hydrocodone) that inhibits ascending pain pathways and alters pain perception, with an analgesic and antipyretic (acetaminophen) that inhibits cyclooxygenase (COX) and central prostaglandin synthesis.
1 to 2 capsules orally every 12 hours, titrated to pain relief. Maximum daily dose: 100 mg naltrexone (equivalent to 100 mg morphine). Capsules must be swallowed whole.
1 to 2 tablets (each containing 7.5 mg hydrocodone bitartrate and 200 mg ibuprofen) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
None Documented
None Documented
Morphine: 2-4 hours; naltrexone: 4-13 hours (active metabolite 6β-naltrexol: 12-18 hours). Clinically, morphine's half-life is prolonged in hepatic or renal impairment.
Hydrocodone: 3.8-6.0 hours in adults; acetaminophen: 2.0-4.0 hours. Clinically, Vicoprofen (hydrocodone/ibuprofen) has an effective half-life of ~4-6 hours for hydrocodone; ibuprofen half-life is 2-4 hours.
Renal: ~60% (morphine), ~20% (naltrexone, in urine as unchanged drug and metabolites); biliary/fecal: ~10% (morphine-3-glucuronide and other metabolites).
Renal excretion of metabolites (hydrocodone: ~60% as conjugates; acetaminophen: ~85-90% as glucuronide and sulfate conjugates). Biliary/fecal elimination accounts for <5%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic